Search results
Immunity Boosting Combination Therapy for Myelodysplastic Syndrome (pre-Leukemia) Treatment: A...
Digital Journal· 4 days agoFREMONT, CA - (NewMediaWire) - May 24, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions ...
Drug Discovery, Development and Evaluation Hub Welcomes New Faculty to Fuel Innovation
UB Reporter· 7 days agoThe University at Buffalo School of Pharmacy and Pharmaceutical Sciences’ (UB SPPS) Drug Discovery, Development and Evaluation (DDDE) Hub, a leading research engine in the fields of pharmaceutical ...
Don’t sweat it: how to find an effective deodorant
The Guardian via Yahoo News· 4 days agoPillai, formerly an engineer, began developing his brand after conventional products not only proved ineffective against odor, but also left him with...
Financial Comparison: Turnstone Biologics (TSBX) vs. Its Competitors
ETF DAILY NEWS· 5 days agoTurnstone Biologics (NASDAQ:TSBX – Get Free Report) is one of 268 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its ...
23andMe Holding Co (ME) Q4 2024 Earnings Call Transcript Highlig
Guru Focus· 4 days agoRevenue: $64 million for Q4, $220 million for the full year, representing a 31% and 27% decrease, respectively, over the same periods in the prior year.Gross P
Bakar Fellows Program Announces 2024 Spark Award Recipients and New Partnership with the Academic...
UC Berkeley NewsCenter· 7 days agoThis year’s Spark Award recipients embody the spirit of innovation and collaboration that defines UC Berkeley’s entrepreneurial ecosystem. From therapeutics for cancer patients ...
Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer - Cogent Biosciences...
Benzinga· 4 days agoCogent Biosciences, Inc. COGT, a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Cole ...
Q4 2024 23andMe Holding Co. Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 4 days agoThe reports are based on statistical models known as polygenic risk scores, developed by 23andMe through our proprietary research database. Our new cancer
“Cell therapies change the definition of human”
Hardwood Paroxysm· 2 days agoThe researcher recently visited Barcelona to present his latest book, Cell harmony (debate) at the Institute of Bioengineering of Catalonia (IBEC), where...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 4 days agoRESEARCH TRIANGLE PARK, N.C., May 23, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that mature Phase 2 results describing the positive impact of trilaciclib administered
